Pephexia Therapeutics ApS: Financial statements 2023
CVR: 41319208
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Pephexia Therapeutics ApS (CVR 41319208) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -3,212,128 and a net result of DKK -5,439,731 compared with DKK -6,677,466 the year before. Equity in the 2023 report amounted to DKK -12,585,942. The company had 3 employees in the financial year.
- Gross Profit
- DKK -3,212,128
- Profit/Loss
- DKK -5,439,731
- Equity
- DKK -12,585,942
- Total Assets
- DKK 5,251,472
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -3.2M | -5.4M | -12.6M | 3 |
| 2022 | - | -5.3M | -6.7M | -7.1M | 3 |
| 2021 | 626K | -4.7M | -4.5M | -2.7M | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Pephexia Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK -5,266,259, and the net result was DKK -6,677,466.
About Pephexia Therapeutics ApS
Pephexia Therapeutics ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Keld Fogtmann Fosgerau. The board consists of Anders Mørkeberg Hinsby (chair), Andrew Justin Stewart Coats, Keld Fogtmann Fosgerau and Mats Peter Blom. The company is owned by Fogtmann Fosgerau Holding ApS and Andrew Justin Stewart Coats. The company has 5 employees (2026). In 2025, the company reported a gross profit of DKK -179,735 and a net result of DKK -4,440,533 compared with DKK -5,320,870 the year before. Equity in the 2025 report amounted to DKK -19,747,345.